检索结果-南通市图书馆

lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia:a randomized controlled study

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第8期21卷 791-798页

作者： Jing SHI Ming-Lu xu Mei-Jiao HE Wan-Lan bo Hai-yu ZHANG Dang-hui sun ding-yu WANG Xiao-yu WANG Qun SHAO yu-Jiao PAN yu ZHANG Chen-Guang DAI Jing-Ying WANG lin-Wei ZHANG Guang-Zhong liU yue li for the GPROT Study Group Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbinChina Department of Gastroenterology the Fourth Affiliated HospitalHarbin Medical UniversityHarbinChina Department of Cardiology Harbin Medical University Cancer HospitalHarbinChina Department of Cardiology Shenzhen People’s HospitalShenzhenChina national Key Laboratory of Frigid Zone Cardiovascular Diseases Harbin Medical UniversityHarbinChina NHC Key Laboratory of Cell Transplantation Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang ProvinceHeilongjiang Province Clinical Medical Research Center for Hypertensionthe First Affiliated HospitalHarbin Medical UniversityHarbinChina Institute of Metabolic Disease Heilongjiang Academy of Medical ScienceHarbinChina 不详

BACKGROUND The prevention of coronary artery disease(CAD)faces dual challenges:the aspirin-induced gastrointestinal injury,and the residual cardiovascular risk after statin *** acetate(Gefarnate)is an anti-ulcer *** was reported that geraniol might participate in lipid metabolism through a variety of *** aim of this study was to assess the lipid-lowering effects of gefarnate in statin-treated CAD patients with residual *** In this prospective,open-label,randomized,controlled trial,69 statin-treated CAD patients with residual hypertriglyceridemia were randomly assigned to gefarnate group and control group,received gefarnate(100 mg/3 times a day)combined with statin and statin alone,*** baseline and after one-month treatment,the levels of plasma triglyceride,high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)and total cholesterol were *** After one-month gefarnate treatment,triglyceride level was significantly lowered from 2.64 mmol/L to 2.12 mmol/L(P=0.0018),LDL-C level lowered from 2.7 mmol/L to 2.37 mmol/L(P=0.0004),HDL-C level increased from 0.97 mmol/L to 1.17mmol/L(P=0.0228).Based on statin therapy,gefarnate could significantly reduce the plasma triglyceride level(P=0.0148)and increase the plasma HDL-C level(P=0.0307).Although the LDL-C and total cholesterol levels tended to decrease,there was no statistically significant *** The addition of gefarnate to statin reduced triglyceride level and increased HDL-C level to a significant extent compared to statin alone in CAD patients with residual *** suggested that gefarnate might provide the dual benefits of preventing gastrointestinal injury and lipid lowering in CAD patients.

关键词： nat alone lipid

3-to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge:Results from a Prospective,Multicenter Study

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2022年第12期35卷 1091-1099页

作者： WANG Jing Ya ZONG Xing yu WU Gui hui QI yuan lin li hui Zhen JI Xin yu TONG lin ZHANG Lei yang Ming bo yang Pu Ye li Ji Ke XIAO Fu Rong ZHANG lin Song HU yun Hong liU Hong De xu Shou Fang sun Sheng WU Wei MAO Ya li Min Qing HOU Hao Hua GONG Zhao yuan GUO yang JIAO li Wen QIN Jin WANG ding Yi WANG Fang GUAN li liN Gang MA Yan WANG Yan Ping SHI nan nan Community Health Service Management Center Dongcheng DistrictBeijing 100700China Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Public Health Clinical Center of Chengdu Chengdu 610066SichuanChina Yiyuan TCM Hospital Zibo 256199ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Xi’an Eighth Hospital Xi’an 710000ShaanxiChina Harbin Infectious Disease Hospital Harbin 150000HeilongjiangChina Hospital(T.C.M)Affiliated to Southwest Medical University Luzhou 646000SichuanChina Xingtai Hospital of Chinese Medicine Xingtai 054000HebeiChina Shijiazhuang Fifth Hospital Shijiazhuang 050000HebeiChina Jiamusi Infectious Disease Hospital Jiamusi 154000HeilongjiangChina Chengde Hospital of Traditional Chinese Medicine Chengde 067040HebeiChina Hanzhong Central Hospital Hanzhong 723000ShaanxiChina Ankang Hospital of Traditional Chinese Medicine Ankang 725000ShaanxiChina Department of Traditional Chinese medicine Dazhou Central HospitalDazhou 635000SichuanChina China national Medicines Corporation Ltd Beijing 100077China Beijing University of Chinese Medicine Beijing 101121China Infectious Disease Hospital of Heilongjiang Province Harbin 150030HeilongjiangChin

Objective Coronavirus disease 2019(COVID-19)and tuberculosis(TB)are major public health and social issues *** long-term follow-up of COVID-19 with pulmonary TB(PTB)survivors after discharge is *** study aimed to comprehensively describe clinical outcomes,including sequela and recurrence at 3,12,and 24 months after discharge,among COVID-19 with PTB *** From January 22,2020 to May 6,2022,with a follow-up by August 26,2022,a prospective,multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13 hospitals from four provinces in *** outcomes,including sequela,recurrence of COVID-19,and PTB survivors,were collected via telephone and face-to-face interviews at 3,12,and 24 months after *** Thirty-two COVID-19 with PTB survivors were *** median age was 52(45,59)years,and 23(71.9%)were *** them,nearly two-thirds(62.5%)of the survivors were moderate,three(9.4%)were severe,and more than half(59.4%)had at least one comorbidity(PTB excluded).The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6%at 3 months to 15.8%at 24 months,with anxiety having a higher proportion over a *** and amnesia recovered at the 12-month follow-up,while anxiety,fatigue,and trouble sleeping remained after ***,one(3.1%)case presented two recurrences of PTB and no re-positive COVID-19during the follow-up *** The proportion of long symptoms in COVID-19 with PTB survivors decreased over time,while nearly one in six still experience persistent symptoms with a higher proportion of *** recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention.

关键词： COVID-19 Pulmonary tuberculosis Long-term Sequela Recurrence Re-positive

Frontiers in high entropy alloys and high entropy functional materials

在线全文

学校读者我要写书评

暂无评论

Rare Metals 2024年第10期43卷 4639-4776页

作者： Wen-Tao Zhang xue-Qian Wang Feng-Qi Zhang Xiao-Ya cui Bing-Bing Fan Jia-Ming Guo Zhi-Min Guo Rui Huang Wen Huang xu-bo li Meng-Ru li Yan Ma Zhi-Hua Shen Yong-Gang sun De-zhuang Wang Fei-yang Wang li-Qiang Wang nan Wang Tian-li Wang Wei Wang Xiao-yang Wang Yi-Han Wang Fu-Jie yu yu-Zhen Yin ling-Kun Zhang Yi Zhang Jian-yang Zhang Qi Zhao yu-Ping Zhao Xin-Dong Zhu Yasir Sohail Ya-nan Chen Tao Feng Qi-Long Gao Hai-Yan He Yong-Jiang Huang Zeng-Bao Jiao Hua Ji Yao Jiang Qiang li Xiao-Ming li Wei-Bing liao Huai-Jun lin hui liu Qi liu Qing-Feng liu Wei-Di liu Xiong-Jun liu yang Lu Yi-Ping Lu Wen Ma xue-Fei Miao Jie Pan Qing Wang Hong-hui Wu yuan Wu Tao yang Wei-Ming yang Qian yu Jin-yu Zhang Zhi-Gang Chen liang Mao yang Ren Bao-Long Shen xun-li Wang Zhe Jia He Zhu Zhen-Duo Wu Si Lan School of Materials Science and Engineering Nanjing University of Science and TechnologyNanjing 210094China Jiangsu Key Laboratory for Advanced Metallic Materials School of Materials Science and EngineeringSoutheast UniversityNanjing 211189China Department of Physics City University of Hong KongHongKong 999077China School of Materials Science and Engineering Tianjin UniversityTianjin 300072China School of Physics and Microelectronics Zhengzhou UniversityZhengzhou 450001China Department of Mechanical Engineering Research Institute for Advanced ManufacturingThe Hong Kong Polytechnic UniversityHong Kong 100872China Center of Electron Microscopy and State Key Laboratory of Silicon Materials School of Materials Science and EngineeringZhejiang UniversityHangzhou 310027China Key Laboratory of Solidification Control and Digital Preparation Technology(liaoning Province) School of Materials Science and EngineeringDalian University of TechnologyDalian 116024China Institute of Advanced Wear&Corrosion Resistance and Functional Materials Jinan UniversityGuangzhou 510632China School of Mechanics and Civil Engineering China University of Mining and TechnologyXuzhou 221116China School of Physical Sciences Great Bay UniversityDongguan 523000China School of Materials Science and Engineering Harbin Institute of TechnologyHarbin 150001China State Key Laboratory of Materials-Oriented Chemical Engineering College of Chemical EngineeringNanjing Tech UniversityNanjing 211816China Beijing Advanced Innovation Center for Materials Genome Engineering Research Institute for Carbon NeutralityUniversity of Science and Technology BeijingBeijing 100083China Department of Mechanical Engineering The University of Hong KongHong Kong 999077China School of Computing Macquarie UniversitySydney 2113Australia Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province College of Physics and Optoelectronic EngineeringShenzhen UniversityShenzhen 518060China State Key Laborato

Owing to their exceptional properties,high-entropy alloys(HEAs)and high-entropy materials have emerged as promising research areas and shown diverse ***,the recent advances in the field are comprehensively reviewed,organized into five *** first section introduces the background of HEAs,covering their definition,significance,application prospects,basic properties,design principles,and *** subsequent section focuses on cutting-edge high-entropy structural materials,highlighting developments such as nanostructured alloys,grain boundary engineering,eutectic systems,cryogenic alloys,thin films,micro-nano-lattice structures,additive manufacturing,high entropy metallic glasses,nano-precipitate strengthened alloys,composition modulation,alloy fibers,and refractory *** the following section,the emphasis shifts to functional materials,exploring HEAs as catalysts,magneto-caloric materials,corrosion-resistant alloys,radiation-resistant alloys,hydrogen storage systems,and materials for ***,the review encompasses functional high-entropy materials outside the realm of alloys,including thermoelectric,quantum dots,nanooxide catalysts,energy storage materials,negative thermal expansion ceramics,and high-entropy wave absorption *** paper concludes with an outlook,discussing future directions and potential growth areas in the *** this comprehensive review,researchers,engineers,and scientists may gain valuable insights into the recent progress and opportunities for further exploration in the exciting domains of high-entropy alloys and functional materials.

关键词： High entropy alloys Cutting-edge structural materials Cutting-edgefunctional materials

Exploring an Integrative Therapy for Treating COVID-19:A Randomized Controlled Trial

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2020年第9期26卷 648-655页

作者： WANG Jia-bo WANG Zhong-xia JING Jing ZHAO Peng DONG Jing-hui ZHOU Yong-feng yang Guang NIU Ming ZHAO xu JIANG Tian-jun Bl Jing-feng xu Zhe ZHANG Ping WU Dan BAI Zhao-fang GUO yu-ming yu Si-miao sun Yong-qiang ZHANG Zi-teng ZHAN Xiao-yan li Peng-yan ding Jin-biao ZHAO Peng-fei SONG xue-ai TANG Jian-yuan HE Dong-chu CHEN Zhu QIN En-qiang WANG Rui-lin XIAO Xiao-he China Military Institute of Chinese Medicine The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Integrative Medical Center The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Treatment and Research Center for Infectious Diseases The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China national Clinical Research Center for Infectious Diseases Beijing(100039)China Department of Radiology The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Research Center for Clinical and Translational Medicine The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated Hospital Chengdu University of Traditional Chinese MedicineChengdu(610075)China College of life Science Beijing University of Chinese MedicineBeijing(100029)China Department of Integrated Treatment General Hospital of Central Theater CommandWuhan(430070)China

Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 ***:A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized,controlled two-arm *** two arms of the trial consist of a control therapy(alpha interferon inhalation,50(x g twice daily;and lopinavir/ritonavir,400 and 100 mg twice daily,respectively)and a testing therapy(control therapy plus Keguan-119.4 g twice daily)by random number table at 1:1 ratio with 24 cases each *** 2-week treatment,adverse events,time to fever resolution,ARDS development,and lung injury on newly diagnosed COVID-19 patients were ***:An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse *** on this result,the study was expanded to include a total of 48 participants(24 cases each arm).The results show that compared with the control arm,the testing arm exhibited a significant improvement in time to fever resolution(P=0.035),and a significant reduction in the development of ARDS(P=0.048).Conclusions:Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.(Trial registration *** 04251871 at ***).

关键词： COVID-19 SARS-CoV-2 acute respiratory distress syndrome Chinese medicine

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su sun-Bin ling Qiao-nan Shan xu-Yong Wei Rui Wang Chang-Ku Jia li zhuang Tian Shen li-Min ding Zhi-Dan xu Lai-Bang Luo li-bo sun Guang-Ming li Tai-Shi Fang nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He lin-Sen Ye yang yang yu-Ting He Wen-Zhi Guo liu-Gen Lan xu-Yong sun Dong Chen Zhi-shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi bo Wang Jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang xuan Wang Zi-Qiang li Mu-Jian Teng Jun-Jie li Wen-Tao Jiang Jian-Hua li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-shun He Zhi-Yong Guo shu-Sen Zheng Xiao xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA Yan ZHU Dong Shan CHEN Ren bo SHI nan nan liU Si Hong FAN Yi Pin WU Gui hui yang Pu Ye BAI Jiang Feng CHEN Hong CHEN li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI liang JIN Hai Hao LEI Xiao li Chun Yan li Min Qing li Qun Tang li Xian Yong liU Hong De liU Jin Ping liU Zhang MA yu Ting MAO Ya MO liu Fen na hui WANG Jing Wei SONG Fang li sun Sheng WANG Dong Ting WANG Ming xuan WANG Xiao Yan WANG Yin Zhen WANG yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun xu Hong Ming xu Shou Fang xuE Rui Xia yang Chun yang Kai Jun yuAN Sheng li ZHANG Gong Qi ZHANG Jin bo ZHANG lin Song ZHAO shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Incidence and Clinical Features of Fetal Growth Restriction in 4 451 Women with Hypertensive Disorders of Pregnancy

在线全文

学校读者我要写书评

暂无评论

Maternal-Fetal Medicine 2020年第4期2卷 207-210页

作者： Zhu yu-Chun lin li li bo-Ya li Xiao-Tian Chen Dun-Jin Zhao Xian-Lan cui Shi-Hong ding Hong-Juan ding Gui-Feng Meng Hai-Xia Wei Hong-Wei sun Xiao-Tong Xin Hong yang hui-Xia Department of Obstetrics and Gynecology Peking University First HospitalBeijing 100034China Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes Mellitus Beijing 100034China Department of Obstetrics Obstetrics and Gynecology Hospital of Fudan UniversityShanghai 200011China Department of Obstetrics and Gynecology Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou 510150China Department of Obstetrics and Gynecology First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Obstetrics and Gynecology Third Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Obstetrics and Gynecology Nanjing Maternity and Child Health Care HospitalNanjing 210004China Department of Obstetrics and Gynecology Urumqi Obstetrics and Gynecology HospitalUrumqi 830001China Department of Obstetrics and Gynecology Affiliated Hospital of Inner Mongolia Medical UniversityHohhot 010050China Department of Obstetrics and Gynecology Guangxi Zhuang Autonomous Region Maternity and Child Health HospitalNanning 530003China Department of Obstetrics and Gynecology Gansu Provincial HospitalLanzhou 730000China Department of Obstetrics and Gynecology Second Hospital of Hebei Medical UniversityShijiazhuang 050000China

Objective:To assess the clinical features of fetal growth restriction(FGR)in women with hypertensive disorders of pregnancy in ***:This is a retrospective cohort *** clinical data of 4451 women with hypertensive disorders of pregnancy were retrospectively collected from 11 tertiary hospitals across ten provinces in China during January 2015 to December *** mean maternal age was(31.0±5.4)years *** were divided into FGR group(n=670)and non-FGR group(n=3781).The incidence and clinical features of FGR,and its correlation with gestational age,previous FGR history,24-hour urinary protein excretion,and hemolysis,elevated liver enzyme and low platelet count(HELLP)syndrome were ***’s t-test and Chi-square test were used when comparing clinical features between FGR and non-FGR ***:The overall incidence of FGR was 15.1%(670/4451).The FGR incidence was 22.4%(433/1937)in women with severe preeclampsia and 18.6%(68/365)in women with chronic hypertension with superimposed preeclampsia,*** was more prevalent in women who had preterm births than those who had term births(22.8%(432/1898)vs.9.3%(238/2553),Plical artery Doppler(13%(87/670)vs.2.4%(89/3781),Plivered earlier than the non-FGR group((35.3±3.0)weeks vs.(36.4±4.3)weeks,P<0.001)with lower birth weight(1731.0±574.5)g vs.(2753.9±902.1)g

关键词： China Fetal growth restriction Hypertension Pregnancy-induced Pre-eclampsia Incidence

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng Ying-hui Jin Tong-Zu liu Fang-Ming Chen De-Gang ding Meng Fu Xin-Quan Gu Bang-Min Han Xing Huang Zhi Hou Wan-li Hu Xin-li Kang Gong-hui li Jian-Xing li Pei-Jun li Chao-Zhao liang Xiu-Heng liu Zhi-yu liu Chun-Xiao liu Jiu-Min liu Guang-Heng Luo Yi Luo Wei-Jun Qin Jian-Hong Qiu Jian-Xin Qiu xue-Jun Shang Ben-Kang Shi Fa sun Guo-Xiang Tian Ye Tian Feng Wang Feng Wang Yin-Huai Wang yu-Jie Wang Zhi-Ping Wang Zhong Wang Qiang Wei Min-hui Xiao Wan-Hai xu Fa-Xian Yi Chao-yang Zhu Qian-yuan zhuang li-Qun Zhou Xiao-Feng Zou Nian-Zeng Xing Da-lin He Xing-Huan Wang 无 Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China Department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China Department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China Department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China Department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China Department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China Department of Urology Qinghai University Affiliated HospitalXi’ning810012China Department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China Department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China Department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China Department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China Department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina Department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China Department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China Department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China Department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China Department of Urology

Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia Recommendation Treatment Guideline

整体毛细管X光透镜在大气颗粒物单颗粒分析中的应用

在线全文

学校读者我要写书评

暂无评论

光学学报 2008年第9期28卷 1833-1836页

作者：孙天希徐光瑜刘志国丁训良朱光华孙洪波刘辉北京师范大学射线束技术与材料改性教育部重点实验室北京师范大学低能核物理研究所北京市辐射中心北京100875 山东水利职业学院日照山东276826

对大气颗粒物进行单颗粒X射线荧光(XRF)分析,是一种识别大气颗粒物来源的有力手段。为了利用实验室X射线光源对大气颗粒物进行单颗粒XRF分析,建立了基于整体毛细管X光透镜和实验室X射线光源的微束X射线谱仪。透镜焦斑处的功率密度增益在... 详细信息

对大气颗粒物进行单颗粒X射线荧光(XRF)分析,是一种识别大气颗粒物来源的有力手段。为了利用实验室X射线光源对大气颗粒物进行单颗粒XRF分析,建立了基于整体毛细管X光透镜和实验室X射线光源的微束X射线谱仪。透镜焦斑处的功率密度增益在103数量级,焦斑直径为30μm左右。该微束X射线谱仪对Fe-Kα线的最小探测极限为0.7 pg。在Mo靶光源电压和电流分别为30 kV和50 mA的条件下,利用该谱仪对直径为9μm的大气颗粒物单颗粒进行XRF分析时,测谱时间在180 s左右。实验表明,基于毛细管X光透镜和实验室X射线光源的微束X射线分析技术在大气颗粒物单颗粒分析中有着潜在的应用价值。

关键词： X射线光学单颗粒XRF分析毛细管X光透镜大气颗粒物